<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365868</url>
  </required_header>
  <id_info>
    <org_study_id>GT-031</org_study_id>
    <nct_id>NCT04365868</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis</brief_title>
  <acronym>NAVIGATE</acronym>
  <official_title>A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galectin Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galectin Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter,&#xD;
      parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability&#xD;
      of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NASH)&#xD;
      cirrhosis and clinical signs of portal hypertension but without esophageal varices at&#xD;
      baseline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in the belapectin treatment groups who develop new esophageal varices at 78 weeks [18 months] of treatment compared to placebo</measure>
    <time_frame>At 78 weeks [18 months]</time_frame>
    <description>Proportion of patients in the belapectin treatment groups who develop new esophageal varices at 78 weeks [18 months] of treatment compared to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop varices (esophageal or gastric) requiring treatment</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop varices (esophageal or gastric) requiring treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop variceal bleed requiring hospitalization</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop variceal bleed requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop clinically significant ascites requiring hospitalization</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop clinically significant ascites requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop spontaneous bacterial peritonitis</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop spontaneous bacterial peritonitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop hepatic encephalopathy (West Haven score ≥2 and requiring hospitalization)</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop hepatic encephalopathy (West Haven score ≥2 and requiring hospitalization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop mortality (all-cause)</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop mortality (all-cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop liver transplant</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop liver transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop model for end-stage liver disease (MELD) score ≥15</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin treatment groups, compared to placebo, who develop model for end-stage liver disease (MELD) score ≥15</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Cumulative incidence rate of patients in the belapectin Phase 3 treatment group who progress to large varices (gastric or esophageal) or develop red wales compared to placebo.</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Cumulative incidence rate of patients in the belapectin Phase 3 treatment group who progress to large varices (gastric or esophageal) or develop red wales compared to placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, progression to large varices or red wales</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, progression to large varices or red wales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, esophageal variceal hemorrhage requiring hospitalization</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, esophageal variceal hemorrhage requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, clinically significant ascites requiring hospitalization</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, clinically significant ascites requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, spontaneous bacterial peritonitis</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, spontaneous bacterial peritonitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, overt hepatic encephalopathy (West Haven score ≥2 and requiring hospitalization)</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, overt hepatic encephalopathy (West Haven score ≥2 and requiring hospitalization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, Child-Turcotte-Pugh (CTP) score increase of ≥2 points (from baseline)</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, Child-Turcotte-Pugh (CTP) score increase of ≥2 points (from baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, model for end-stage liver disease (MELD) score increase to ≥15 as measured on 2 consecutive occasions</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, model for end-stage liver disease (MELD) score increase to ≥15 as measured on 2 consecutive occasions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, liver transplant</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, liver transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Event-free survival by time to first cirrhosis related clinical event, liver-related death</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Event-free survival by time to first cirrhosis related clinical event, liver-related death</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory Efficacy:Change in liver stiffness measurement (LSM), baseline-adjusted, as determined by vibration controlled transient elastography (VCTE) (FibroScan) exams during Phase 2b and Phase 3</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Change in liver stiffness measurement (LSM), baseline-adjusted, as determined by vibration controlled transient elastography (VCTE) (FibroScan) exams during Phase 2b and Phase 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory Efficacy: Difference in Chronic Liver Disease Questionnaire (CLDQ) scores between belapectin and placebo treatment during Phase 2b and Phase 3</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>The difference in Chronic Liver Disease Questionnaire scores between belapectin and placebo treatment during Phase 2b and Phase 3 will be observed; Subject responses to the questionnaire are based on a scale from 1 to 7, with 1 being maximum frequency and 7 being none at all. Scores indicative of higher frequency, indicate worse outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety: Incidence of adverse events</measure>
    <time_frame>Through study end, 78 weeks or 156 weeks</time_frame>
    <description>Incidence of adverse events</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1010</enrollment>
  <condition>Prevention of Esophageal Varices</condition>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>belapectin 2 mg/kg lean body mass (LBM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2b: Belapectin 2 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)&#xD;
Phase 3: The patient will be switched to the optimal dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>belapectin 4 mg/kg lean body mass (LBM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 2b: Belapectin 4 mg/kg lean body mass administered intravenously (IV) every other week for 78 weeks (18 months)&#xD;
Phase 3: The patient will be switched to the optimal dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phase 2b: Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)&#xD;
Phase 3:Placebo, administered intravenously (IV) every other week for 78 weeks (18 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>belapectin</intervention_name>
    <description>intravenous</description>
    <arm_group_label>belapectin 2 mg/kg lean body mass (LBM)</arm_group_label>
    <arm_group_label>belapectin 4 mg/kg lean body mass (LBM)</arm_group_label>
    <other_name>GR-MD-02</other_name>
    <other_name>galactoarabino rhamnogalacturonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intravenous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each subject must meet all of the following criteria to be enrolled in this study:&#xD;
&#xD;
          1. Is male or female, ≥ 18 and ≤ 75 years of age at the time of Screening.&#xD;
&#xD;
          2. Is willing and able to provide written informed consent prior to the initiation of any&#xD;
             study-specific procedures.&#xD;
&#xD;
          3. Has evidence of portal hypertension, with either one of the following:&#xD;
&#xD;
               1. platelet count &lt;150,000/mm3&#xD;
&#xD;
               2. documented HVPG measurement &gt;6 mmHg&#xD;
&#xD;
                  OR&#xD;
&#xD;
               3. at least two of the following:&#xD;
&#xD;
                    -  spleen size ≥14 cm (documented by ultrasound, MRI, or CT scan)&#xD;
&#xD;
                    -  abdominal collateral circulation (documented by ultrasound, MRI, or CT scan&#xD;
                       or physical examination, ie, caput medusae)&#xD;
&#xD;
                    -  documented liver transient elastography (eg, FibroScan) ≥20 kPa.&#xD;
&#xD;
          4. Has a history confirming nonalcoholic steatohepatitis (NASH) cirrhosis, with at least&#xD;
             one of the following:&#xD;
&#xD;
               -  There is a historical liver biopsy showing cirrhosis with steatohepatitis. There&#xD;
                  is no evidence for a competing etiology for the cirrhosis.&#xD;
&#xD;
               -  There is a historical liver biopsy showing steatohepatitis, and there is evidence&#xD;
                  of cirrhosis from clinical or imaging data or a second liver biopsy showing&#xD;
                  cirrhosis without all features of NASH (as the histological NASH lesions may have&#xD;
                  burnt out). There is no evidence for a competing etiology. There is at least 1&#xD;
                  co-existing metabolic comorbidity at Screening: obesity (with either body mass&#xD;
                  index [BMI] ≥30 kg/m2 or waist circumference ≥102 cm [40 in, men] or ≥88 cm [35&#xD;
                  in, women], or by ethnically appropriate cutpoints); hypertension (either on anti&#xD;
                  hypertensive drug therapy for at least 1 year or systolic/diastolic blood&#xD;
                  pressure (BP) &gt;140/80 mm Hg); Type 2 diabetes (glycated hemoglobin [HbA1c] ≥6.5%,&#xD;
                  or on anti-diabetic medication for at least 1 year); or dyslipidemia&#xD;
                  (triglycerides ≥150 mg/dL or on drug therapy for hypertriglyceridemia for at&#xD;
                  least 6 months; high-density lipoprotein cholesterol ≤40 mg/dL [men] or ≤50 mg/dL&#xD;
                  [women]) to corroborate a diagnosis of nonalcoholic fatty liver disease (NAFLD).&#xD;
&#xD;
               -  There is a historical liver biopsy showing cirrhosis with steatosis but not&#xD;
                  steatohepatitis. There is no evidence for a competing etiology. There are at&#xD;
                  least 2 co-existing (or history of) metabolic comorbidities (with obesity or&#xD;
                  diabetes being one of them) to corroborate a diagnosis of NAFLD.&#xD;
&#xD;
               -  There is a historical liver biopsy showing steatosis but now with cirrhosis&#xD;
                  either by clinical examination, imaging, or biopsy. If there is a current biopsy,&#xD;
                  it does not show evidence of steatosis or steatohepatitis as histological lesions&#xD;
                  may have burned out. There is no evidence for a competing etiology. There are at&#xD;
                  least 2 co existing (or history of) metabolic comorbidities (with obesity or&#xD;
                  diabetes being one of them) to corroborate a diagnosis of NAFLD.&#xD;
&#xD;
               -  For patients without a historical liver biopsy with slides available for review&#xD;
                  by the central study pathologist, a screening liver biopsy is required.&#xD;
&#xD;
             Note: All liver biopsy blocks and/or slides for eligibility assessments (including&#xD;
             those from historical biopsies) will be reviewed by the central study pathologist&#xD;
             while the subject is in Screening, and must meet definitions for diagnosis of either&#xD;
             Definitive cirrhosis or Probable cirrhosis. Results from the central study pathologist&#xD;
             must be available before the subject is randomized.&#xD;
&#xD;
          5. Absence of hepatocellular carcinoma (HCC) by valid imaging (eg, ultrasound, CT scan,&#xD;
             or MRI) within 6 months prior to randomization. If no such imaging result is&#xD;
             available, then ultrasound imaging should be performed as part of standard of care.&#xD;
&#xD;
          6. Patients with diabetes mellitus can be enrolled, if they are adequately controlled on&#xD;
             a stable dose or doses of antidiabetic medication(s) for at least 3 months before&#xD;
             Screening, and their screening HbA1c is ≤9.5%.&#xD;
&#xD;
          7. Patients on vitamin E or pioglitazone can be enrolled if they are on a stable dose and&#xD;
             regimen for at least 3 months before screening, and the dose is expected to be held&#xD;
             constant during the trial.&#xD;
&#xD;
          8. Patients on a statin can be enrolled if they are on a stable regimen for at least 3&#xD;
             months before Screening, and expected to be held stable during the trial.&#xD;
&#xD;
          9. Is not pregnant and must have a negative serum pregnancy test result prior to&#xD;
             randomization.&#xD;
&#xD;
         10. Is of non-childbearing potential or if a fertile man or woman participating in&#xD;
             heterosexual relations, agrees to use two acceptable means of contraception (ie, 2&#xD;
             effective methods of contraception, one of which must be a physical barrier method&#xD;
             [eg, male or female condom, diaphragm] when combined with a highly effective method of&#xD;
             contraception [ie, a method with a failure rate of &lt;1% per year when used consistently&#xD;
             and correctly]) throughout his/her participation in this study and for 90 days after&#xD;
             discontinuation of study treatment.&#xD;
&#xD;
             Highly effective forms of contraception include:&#xD;
&#xD;
               -  combined (estrogen and progestogen containing) hormonal contraception associated&#xD;
                  with inhibition of ovulation (such as oral, intravaginal, transdermal) methods&#xD;
&#xD;
               -  progestogen-only hormonal contraception associated with inhibition of ovulation&#xD;
                  (such as oral, injectable, implantable)&#xD;
&#xD;
               -  hormone-releasing intrauterine system (IUS)&#xD;
&#xD;
               -  intrauterine device (IUD)&#xD;
&#xD;
               -  bilateral tubal occlusion&#xD;
&#xD;
               -  a vasectomized partner, provided that partner is the sole sexual partner of the&#xD;
                  women of childbearing potential trial participant and that the vasectomized&#xD;
                  partner has received medical assessment of the surgical success&#xD;
&#xD;
               -  sexual abstinence (ie, a refraining from heterosexual intercourse during the&#xD;
                  entire period of the clinical trial, if it is the preferred and usual lifestyle&#xD;
                  of the subject).&#xD;
&#xD;
             Surgically sterile males and females are not required to use contraception provided&#xD;
             they have been considered surgically sterile for at least 6 months. Surgical sterility&#xD;
             includes history of surgically successful vasectomy, hysterectomy, or bilateral&#xD;
             salpingo-oophorectomy. Postmenopausal women who have been amenorrheic for at least 2&#xD;
             years at the time of Screening will be considered sterile.&#xD;
&#xD;
         11. If a lactating woman, agrees to discontinue nursing before the start of study&#xD;
             treatment and refrain from nursing until 90 days after the last dose of study&#xD;
             treatment.&#xD;
&#xD;
         12. If a man, agrees to refrain from sperm donation throughout the study period and for a&#xD;
             period of 90 days following the last dose of investigational medicinal product (IMP).&#xD;
             Female subjects may not begin a cycle of ova donation or harvest throughout the study&#xD;
             period and for a period of 90 days following the last dose of IMP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Presence of esophageal, gastroesophageal, or isolated gastric varices, based on an&#xD;
             upper gastrointestinal (GI) esophagogastroduodenoscopy (EGD) exam conducted during&#xD;
             Screening. Patients with portal hypertensive gastropathy could be enrolled.&#xD;
&#xD;
          2. History of hepatic cirrhosis decompensation including any episode of variceal&#xD;
             bleeding, ascites not controlled by medication, spontaneous bacterial peritonitis or&#xD;
             overt hepatic encephalopathy (West Haven grade ≥2 as assessed by the principal&#xD;
             investigator), OR develops signs of hepatic cirrhosis decompensation during Screening.&#xD;
&#xD;
          3. Known or suspected abuse of alcohol (&gt;20 g/day for women or &gt;30 g/day for men [on&#xD;
             average per day]), as per medical history. Significant alcohol consumption is defined&#xD;
             as more than 20 grams per day in females and more than 30 grams per day in males. On&#xD;
             average, a standard drink in the United States is considered to be 14 grams of&#xD;
             alcohol, equivalent to 12 fluid ounces of regular beer (5% alcohol), 5 fluid ounces of&#xD;
             table wine (12% alcohol), or 1.5 fluid ounces of 80 proof spirits (40% alcohol).&#xD;
&#xD;
          4. Alcohol dependence (ie, a score &gt;8 on the Alcohol Use Disorders Identification Test)&#xD;
&#xD;
          5. Narcotics or any other drug abuse or dependence in the last 5 years&#xD;
&#xD;
          6. Prior trans-jugular intrahepatic portal-systemic (TIPS) shunt procedure&#xD;
&#xD;
          7. Documented causes of liver disease other than NASH, including but not restricted to:&#xD;
&#xD;
               -  Viral hepatitis, unless eradicated at least 3 years prior to Screening&#xD;
&#xD;
                    -  acute hepatitis A infection (presence of hepatitis A immunoglobulin M [IgM]&#xD;
                       at Screening)&#xD;
&#xD;
                    -  positive hepatitis B surface antigen&#xD;
&#xD;
                    -  positive hepatitis C virus (HCV) ribonucleic acid (to be performed prior to&#xD;
                       randomization in case of positive HCV antibody)&#xD;
&#xD;
               -  Documented drug-induced liver disease&#xD;
&#xD;
               -  Alcoholic liver disease&#xD;
&#xD;
               -  Autoimmune hepatitis&#xD;
&#xD;
               -  Wilson's disease&#xD;
&#xD;
               -  Hemochromatosis&#xD;
&#xD;
               -  Primary biliary cholangitis&#xD;
&#xD;
               -  Primary sclerosing cholangitis&#xD;
&#xD;
               -  Genetic hemochromatosis&#xD;
&#xD;
               -  History or planned liver transplantation&#xD;
&#xD;
               -  Alpha-1 antitrypsin deficiency&#xD;
&#xD;
          8. History of human immunodeficiency virus (HIV), or positive HIV test at Screening&#xD;
&#xD;
          9. Any of the following test or score:&#xD;
&#xD;
               -  serum alanine aminotransferase (ALT) &gt; 5 × upper limit of normal (ULN)*&#xD;
&#xD;
               -  serum aspartate aminotransferase (AST) &gt; 5 × ULN*&#xD;
&#xD;
                  *Screening values will be obtained at SV1 and SV2 (which will be separated by 2&#xD;
                  to 4 weeks). A second screening value that is &gt;50% higher than the first value&#xD;
                  should prompt re-evaluation of the severity of the underlying liver disease and&#xD;
                  eligibility for this trial. If a transaminase level at SV2 is &gt;33% different from&#xD;
                  the level at SV1, then additional measurements should be performed at SV3. In&#xD;
                  such cases, the baseline transaminase levels will be established for subjects&#xD;
                  using the mean value of 4 evaluations [ie, at SV1, SV2, SV3, and Baseline (ie,&#xD;
                  pre-dose during Visit 1)].&#xD;
&#xD;
               -  serum ALP &gt; 2 × ULN&#xD;
&#xD;
               -  mean platelet count &lt; 50,000/mm3&#xD;
&#xD;
               -  total bilirubin ≥ 2.0 mg/dL (subjects with a documented history of Gilbert's&#xD;
                  syndrome can be enrolled if the direct bilirubin is within normal reference&#xD;
                  range)&#xD;
&#xD;
               -  model for end-stage liver disease (MELD) score ≥12&#xD;
&#xD;
               -  Child-Turcotte-Pugh (CTP) Score ≥7 Note: Following Phase 2b, subjects with CTP&#xD;
                  scores ≥7 may be enrolled if recommended* by the Data Safety Monitoring Board&#xD;
                  (DSMB) and approved by the Trial Steering Committee (TSC), based on the planned&#xD;
                  interim analysis (IA). [*based on DSMB review of preliminary results from a&#xD;
                  separate hepatic impairment clinical trial (Study GT-032) which is assessing&#xD;
                  belapectin safety and PK in cirrhotic subjects with CTP scores ≥7.&#xD;
&#xD;
               -  estimated glomerular filtration rate &lt; 45 mL/min* *Note: per Modification of Diet&#xD;
                  in Renal Disease algorithm&#xD;
&#xD;
         10. Taking an angiotensin converting enzyme inhibitor, angiotensin II receptor blocker, or&#xD;
             β-1 selective adrenergic receptor inhibitor, unless on a stable regimen for at least 3&#xD;
             months prior to Screening and no changes in the regimen are anticipated during the&#xD;
             study. Subjects taking a non-selective beta blocker are not eligible to be enrolled&#xD;
             (Investigators are encouraged to substitute another medication, if clinically&#xD;
             warranted).&#xD;
&#xD;
         11. History of major surgery during Screening.&#xD;
&#xD;
         12. History of a solid organ transplant requiring immunosuppressive therapy.&#xD;
&#xD;
         13. History of bariatric surgery within 1 year of randomization, or plan to undergo&#xD;
             bariatric surgery during the study.&#xD;
&#xD;
         14. Has positive screening test for illicit drugs of abuse at Screening.&#xD;
&#xD;
         15. Has participated in an investigational new drug study within 30 days or 5 half-lives&#xD;
             whichever is longer, prior to randomization.&#xD;
&#xD;
         16. Has a history of malignancy within 5 years of randomization, except for basal cell&#xD;
             carcinoma, squamous cell carcinoma, and adequately treated in situ uterine cervical&#xD;
             cancer.&#xD;
&#xD;
         17. Has clinically significant cardiovascular disease (eg, uncontrolled hypertension,&#xD;
             myocardial infarction, unstable angina), New York Heart Association Grade II or&#xD;
             greater congestive heart failure, serious cardiac arrhythmia requiring intervention&#xD;
             (eg, pacemaker/ablation) or Grade II or greater peripheral vascular disease.&#xD;
&#xD;
         18. Has a history of clinically significant hematologic, renal, hepatic, pulmonary,&#xD;
             neurological, psychiatric, gastrointestinal, systemic inflammatory, metabolic or&#xD;
             endocrine disorder or any other condition that, in the opinion of the Investigator,&#xD;
             renders the subject a poor candidate for inclusion into the study.&#xD;
&#xD;
         19. Has known allergies to the IMP or any of its excipients.&#xD;
&#xD;
         20. Has previously received belapectin within 6 months of randomization.&#xD;
&#xD;
         21. Is an employee or family member of the Investigator or study center personnel.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pol Boudes, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Galectin Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pol Boudes, M.D.</last_name>
    <phone>678-620-3186</phone>
    <email>boudes@galectintherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Hyatt</last_name>
      <email>stacyhyatt@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Meagan Gray, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Health Specialists</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Barnes</last_name>
      <email>dbarnes@dothangi.com</email>
    </contact>
    <investigator>
      <last_name>Scott Sarrels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute for Liver Health</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selina Castillo</last_name>
      <phone>480-470-4000</phone>
      <email>scastillo@azliver.com</email>
    </contact>
    <investigator>
      <last_name>Anita Kohli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Liver Health - Glendale</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanja Obradov</last_name>
      <phone>480-470-4000</phone>
      <phone_ext>122</phone_ext>
      <email>sobradov@azliver.com</email>
    </contact>
    <investigator>
      <last_name>Ann Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Liver Health - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristina Dickinson</last_name>
      <phone>520-433-0154</phone>
      <email>kdickinson@azliver.com</email>
    </contact>
    <investigator>
      <last_name>Naim Alkhouri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Wellness Center - Little Rock</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205-6414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Counts</last_name>
      <phone>501-687-9300</phone>
      <email>kcounts@adclr.com</email>
    </contact>
    <investigator>
      <last_name>Alonzo Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research, Inc.</name>
      <address>
        <city>Canoga Park</city>
        <state>California</state>
        <zip>91303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anitha Roobalingam</last_name>
      <email>aroobalingam@hopeclinical.com</email>
    </contact>
    <investigator>
      <last_name>Hessam Aazami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern California GI &amp; Liver Centers</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasey Seyer</last_name>
      <phone>619-964-9649</phone>
      <email>kseyer@researchscrc.com</email>
    </contact>
    <investigator>
      <last_name>Tarek Hassanein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Medical Center -La Jolla Multi-Specialty Clinics- Perlman Offices</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra Encinas</last_name>
      <phone>858-246-2302</phone>
      <email>aencinas@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Rohit Loomba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Om Research LLC</name>
      <address>
        <city>Lancaster</city>
        <state>California</state>
        <zip>93534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Blunt</last_name>
      <phone>661-388-2239</phone>
      <phone_ext>5</phone_ext>
      <email>hblunt@omclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Jatinder Pruthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aileen Alon</last_name>
      <email>aileen.alon@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Mazen Noureddin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>inSite Digestive Health Care - Orange</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Falcon</last_name>
      <email>tfalcon.krc480@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alaa Abousaif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misty Guillen</last_name>
      <email>misty.guillen@caliverresearch.org</email>
    </contact>
    <investigator>
      <last_name>Edward Mena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Lopez</last_name>
      <phone>909-883-2999</phone>
      <email>elopez@ieliverfoundation.com</email>
    </contact>
    <investigator>
      <last_name>Zeid Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Anschutz Medical Campus</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingeborg Cuba</last_name>
      <phone>786-262-0028</phone>
      <email>ingeborg.cuba@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Wieland, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peak Gastroenterology Associates</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907-6262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keyur Patel</last_name>
      <phone>719-663-8590</phone>
      <email>kpatel@peakgasto.com</email>
    </contact>
    <investigator>
      <last_name>Bhaktasharan Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integrity Clinical Research, LLC (ICR SITES) - Doral</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Miguel Garcia</last_name>
      <phone>305-552-7660</phone>
      <email>jmgarcia@icrsites.com</email>
    </contact>
    <investigator>
      <last_name>Linda Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research, LLC</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Gray</last_name>
      <phone>352-563-1865</phone>
      <email>lgray@encoredocs.com</email>
    </contact>
    <investigator>
      <last_name>Paul Hellstern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leta Smith</last_name>
      <phone>941-727-7772</phone>
      <email>leta.smith@fdhs.com</email>
    </contact>
    <investigator>
      <last_name>Arun Khazanchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ClinCloud LLC</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751-3320</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Schirtzer</last_name>
      <email>eschirtzer@myclincloud.com</email>
    </contact>
    <investigator>
      <last_name>Esteban Olivera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Pharma CR, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33147</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mirna Bombino</last_name>
      <email>mbombino@advancedpharmacr.com</email>
    </contact>
    <investigator>
      <last_name>Kimberly Cruz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genoma Research Group, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Lucia</last_name>
      <email>lauralucia@genoma.comcastbiz.net</email>
    </contact>
    <investigator>
      <last_name>Angel Vento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sensible Healthcare</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Che-LaRue</last_name>
      <phone>407-654-2724</phone>
      <email>mche@sensiblehealthcare.net</email>
    </contact>
    <investigator>
      <last_name>William Bowman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guardian Angel Health Services, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Porro</last_name>
      <phone>786-308-1157</phone>
      <email>lporrod@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Angel Rosario, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Medical Center &amp; Research</name>
      <address>
        <city>Zephyrhills</city>
        <state>Florida</state>
        <zip>33542</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy Hodock</last_name>
      <phone>813-780-8368</phone>
      <phone_ext>80150</phone_ext>
      <email>thodock@floridamedicalclinic.com</email>
    </contact>
    <investigator>
      <last_name>Tawfik Chami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Healthcare of Georgia, P.C.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurt Rivera</last_name>
      <phone>404-723-1965</phone>
      <email>krivera@digestivehealthcare.net</email>
    </contact>
    <investigator>
      <last_name>Michael Galambos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Central Georgia, LLC</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenji Yoshida</last_name>
      <email>kyoshida@gaocg.com</email>
    </contact>
    <investigator>
      <last_name>Shahriar Sedghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia, PC</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katyria Thornton</last_name>
      <phone>678-819-4217</phone>
      <email>kthornton@gigeorgia.com</email>
    </contact>
    <investigator>
      <last_name>Aasim Sheikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loyola University Health System</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sana Iqbal</last_name>
      <phone>708-216-3268</phone>
      <email>siqbal5@luc.edu</email>
    </contact>
    <investigator>
      <last_name>Natasha Von Roenn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IU Health University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Cruz</last_name>
      <phone>317-278-1664</phone>
      <email>mandcruz@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Raj Vuppalanchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michiana Gastroenterology, Inc.</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daijon Frazier</last_name>
      <email>daijon.frazier@objectivegi.com</email>
    </contact>
    <investigator>
      <last_name>Pankaj Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas Medical Clinic PA</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Knoebber-Carr</last_name>
      <email>kknoebbercarr@kmcpa.com</email>
    </contact>
    <investigator>
      <last_name>Shekhar Challa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tandem Clinical Research, LLC</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Bennett</last_name>
      <phone>504-934-8424</phone>
      <email>abennett@tandemclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Gary Reiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane Cancer Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-2600</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Boss</last_name>
      <email>eboos@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Fredric Regenstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy Medical Center - The Institute for Digestive Health and Liver Disease</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111-1552</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Obinna Abalihi</last_name>
      <email>oabalihi@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Raza Malik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorela Myftiu</last_name>
      <phone>734-763-6998</phone>
      <email>mlorela@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Hari Conjeevaram, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System - Hemophilia and Thrombosis Treatment Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjorie Wood</last_name>
      <email>mwood5@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Stuart Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Western Michigan</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athena Kinsman</last_name>
      <email>akinsman@gastro-assoc-wm.com</email>
    </contact>
    <investigator>
      <last_name>Allan Coates, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southern Therapy and Advanced Research (STAR) - Jackson</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Logan James</last_name>
      <phone>769-251-5674</phone>
      <email>ljames@jacksonliverandgi.com</email>
    </contact>
    <investigator>
      <last_name>Brian Borg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Research Institute</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Lynn</last_name>
      <phone>816-759-5274</phone>
      <email>LLynn@kcresearchinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Bradley Freilich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Excel Clinical Research - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109-6209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miasimone Glasco</last_name>
      <email>mglasco@excelclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Duane Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olia Ali</last_name>
      <email>olia.ali@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Ilan Weisberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-6402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Kerr</last_name>
      <phone>646-501-9624</phone>
      <email>kimberly.kerr@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Viviana Figueroa Diaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Hospital/Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Peterson</last_name>
      <email>rhp2003@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Sonal Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moury Minhaz</last_name>
      <email>mm3597@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Julia Wattacheril, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cumberland Research Associates, LLC</name>
      <address>
        <city>Fayetteville</city>
        <state>North Carolina</state>
        <zip>28304-3571</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Person</last_name>
      <phone>910-484-8163</phone>
      <email>aperson@cumberlandresearchassociates.com</email>
    </contact>
    <investigator>
      <last_name>John Poulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucas Research</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rike Eitner</last_name>
      <phone>252-222-5700</phone>
      <phone_ext>129</phone_ext>
      <email>rike.eitner@lucasresearch.org</email>
    </contact>
    <investigator>
      <last_name>Kathryn Lucas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consultants for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Smita Singh</last_name>
      <email>ssingh@ohiogi.com</email>
    </contact>
    <investigator>
      <last_name>Ravi Ravinuthala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Company, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Daria</last_name>
      <phone>513-584-5245</phone>
      <email>dariade@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Nadeem Anwar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Hernandez</last_name>
      <email>carla.hernandez@uhhospitals.org</email>
    </contact>
    <investigator>
      <last_name>Pierre Gholam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anitha Guduri</last_name>
      <email>anitha.guduri@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Na Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Jefferson Digestive Health Institute - Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia MIller</last_name>
      <phone>215-955-8108</phone>
      <email>cynthia.l.miller.3@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Dina Halegoua-De Marzio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center (UPMC) - The Center for Liver Diseases</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maris Leonard</last_name>
      <email>leonardm6@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Jaideep Behari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Halim Bou Daher</last_name>
      <email>boudaher@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Don Rockey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Galen Medical Group - Ziegler Plaza</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37343-5470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Norwood</last_name>
      <phone>423-954-9015</phone>
      <email>kim.norwood@galenmedical.com</email>
    </contact>
    <investigator>
      <last_name>Chirag Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Diabetes &amp; Endocrine Consultants</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Jones</last_name>
      <phone>423-265-3561</phone>
      <phone_ext>106</phone_ext>
      <email>mjones@drhuffman.com</email>
    </contact>
    <investigator>
      <last_name>David Huffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastro One - GI Diagnostic and Therapeutic Endoscopy Center - 1310 Wolf Park</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela McArthur</last_name>
      <email>amcarthur@gastro1.com</email>
    </contact>
    <investigator>
      <last_name>Ziad Younes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associates in Gastroenterology</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Carrington</last_name>
      <email>mcarrington@digestivehealthresearch.com</email>
    </contact>
    <investigator>
      <last_name>George James, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Clinical Research Institute, LLC</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margie Urbina</last_name>
      <phone>817-471-1070</phone>
      <email>margieurbina@tcri.us</email>
    </contact>
    <investigator>
      <last_name>Reem Ghalib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liver Specialists of Texas</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78757</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Perez</last_name>
      <phone>210-253-3426</phone>
      <email>jenperez@txliver.com</email>
    </contact>
    <investigator>
      <last_name>Carmen Landaverde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Transplant Physicians</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shandra Silas</last_name>
      <phone>214-947-1287</phone>
      <email>shandrasilas@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Parvez Mantry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texoma Liver Center PLLC. - Denison</name>
      <address>
        <city>Denison</city>
        <state>Texas</state>
        <zip>75020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Hassan</last_name>
      <phone>469-819-0228</phone>
      <email>admin@somaclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Hesham Elgouhari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Texas Research Institute</name>
      <address>
        <city>Edinburg</city>
        <state>Texas</state>
        <zip>78539</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Leal</last_name>
      <phone>956-284-6353</phone>
      <email>margaret.leal@southtexasresearchinstitute.com</email>
    </contact>
    <investigator>
      <last_name>Rashmee Patil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine - Baylor Clinic - Abdominal Transplant &amp; Liver Disease Clinic</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Lee</last_name>
      <email>janal@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>John Vierling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions Inc - Houston - Stancliff Rd</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazli Hemani</last_name>
      <phone>713-333-9323</phone>
      <email>nazli@pioneerresearchsolutions.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Velazquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Texas Liver Institute, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodney Ray</last_name>
      <phone>210-253-3426</phone>
      <phone_ext>8998</phone_ext>
      <email>rray@txliver.com</email>
    </contact>
    <investigator>
      <last_name>Eric Lawitz, MD, FAASLD, AGAF, FAPCR, CPI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Candace Faye</last_name>
      <phone>210-982-0320</phone>
      <email>cfaye@pinnacleresearch.com</email>
    </contact>
    <investigator>
      <last_name>Stephen Harrison, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Health Care - UUHC - Kidney &amp; Liver Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alyssa Mills</last_name>
      <email>alyssa.mills@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Juan Gallegos-Orozco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia School of Medicine</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Laskey</last_name>
      <email>gal5u@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Caldwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Fredericksburg</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401-8425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Hodges</last_name>
      <phone>850-287-9517</phone>
      <email>ashley.hodges@objectivegi.com</email>
    </contact>
    <investigator>
      <last_name>Dharel Narayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia - Newport News</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naketa Bartlet</last_name>
      <phone>757-947-3197</phone>
      <email>Naketa_Bartlett@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours Liver Institute of Virginia - Richmond</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Cornwell</last_name>
      <phone>804-977-8922</phone>
      <email>Sarah_Cornwell@bshsi.org</email>
    </contact>
    <investigator>
      <last_name>Mitchell Shiffman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Meador</last_name>
      <phone>804-675-6407</phone>
      <email>jill.meador@va.gov</email>
    </contact>
    <investigator>
      <last_name>Michael Fuchs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Spokane</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202-3462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flori Mantello</last_name>
      <phone>509-505-6227</phone>
      <email>fmantello@velocityclinical.com</email>
    </contact>
    <investigator>
      <last_name>Harold Preiksaitis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <zip>2750</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Hemmings</last_name>
      <email>catherine.hemmings@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Martin Weltman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Morgan</last_name>
      <email>joanne.morgan@sa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Edmund Tse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Dimitri</last_name>
      <email>emma.dimitri@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Amanda Nicoll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre Clayton</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid deJong</last_name>
      <email>ingrid.dejong@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander Hodge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Lam</last_name>
      <email>wendy.lam@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Oyekoya Ayonrinde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lotte Schoenmakers</last_name>
      <email>lotte.schoenmakers@uza.be</email>
    </contact>
    <investigator>
      <last_name>Sven Francque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire De Bruxelles Hôpital Erasme VZW</name>
      <address>
        <city>Brussels</city>
        <state>BEL</state>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francoise Smits</last_name>
      <email>francoise.smits@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Christophe Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <state>VOV</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tinneke Delvaeye</last_name>
      <email>tinneke.delvaeye@azmmsj.be</email>
    </contact>
    <investigator>
      <last_name>Christophe Van Steenkiste, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>VOV</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ilse Senesael</last_name>
      <email>ilse.senesael@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Anja Geerts, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe sante CHC - Clinique du MontLegia</name>
      <address>
        <city>Liège</city>
        <state>WLG</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandro Maniglia</last_name>
      <phone>+32 4 224 89 92</phone>
      <email>alexandro.maniglia@chc.be</email>
    </contact>
    <investigator>
      <last_name>Boris Bastens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Calgary - Heritage Medical Research Clinic - Foothills Hospital Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Cole</last_name>
      <email>coles@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Mark Swain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Gastroenterology Associates</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ancheta-Schmit</last_name>
      <phone>(604) 688-6332</phone>
      <email>maria.a.schmit@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alnoor Ramji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brampton Civic Hospital</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6R 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Bojarski</last_name>
      <email>Sharon.Bojarski@williamoslerhs.ca</email>
    </contact>
    <investigator>
      <last_name>Natasha Chandok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachida Fahem</last_name>
      <phone>+33 3 22 08 88 40</phone>
      <email>fahem.rachida@chu-amiens.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Nguyen-Khac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Severine Donneger</last_name>
      <email>severine.donneger@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Lorraine Blaise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure Mazialivoua</last_name>
      <email>annelaure.mazialivoua@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Leroy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Guigard</last_name>
      <email>IGuigard@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Charlotte Costentin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils De Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahe Raffin</last_name>
      <phone>+33 4 72 07 11 76</phone>
      <email>mahe.raffin@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Massimo Levrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Montpellier - Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34090</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Saint-Haont</last_name>
      <email>b-sainthaont@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Stephanie Faure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hôpital Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saïda Benzerafa</last_name>
      <phone>+33 3 83 15 33 55</phone>
      <email>s.benzerafa@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Bronowicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - L'Archet</name>
      <address>
        <city>Nice</city>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Vallee</last_name>
      <phone>+33 4 92 03 94 06</phone>
      <email>vallee.d@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Albert Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mina Ahloulay</last_name>
      <phone>+33 1 58 41 29 88</phone>
      <email>mina.ahloulay@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Sogni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline Simo-Noumbissie</last_name>
      <phone>+33 3 69 55 16 80</phone>
      <email>pauline.simo-noumbissie@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Francois Habersetzer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin der Johannes Gutenberg-Universitat Mainz</name>
      <address>
        <city>Mainz</city>
        <state>RP</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Depoix</last_name>
      <email>susan.depoix@unimedizin-mainz.de</email>
    </contact>
    <investigator>
      <last_name>Jorn Schattenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>EUGASTRO GmbH</name>
      <address>
        <city>Leipzig</city>
        <state>SN</state>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvonne Maybaum</last_name>
      <email>yvonne.maybaum@eugastro.de</email>
    </contact>
    <investigator>
      <last_name>Ingolf Schiefke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Goethe-Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nastasja Diener</last_name>
      <email>nastasja.diener@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Anita Pathil-Warth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irena Kantor</last_name>
      <email>kantorir@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Ohad Etzion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vered Ben Hakoon</last_name>
      <email>v_ben-hakoon@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ella Veitsman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hen Biton</last_name>
      <email>henbi@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Eli Zuckerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rami Ghantous</last_name>
      <email>ramighantous@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Rifaat Safadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Family Hospital</name>
      <address>
        <city>Nazareth</city>
        <zip>16100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kholoud Fahoum</last_name>
      <email>kholoud.fahoum@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Rifaat Safadi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Hospital</name>
      <address>
        <city>Petah Tiqwa</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shulamith Greenstein</last_name>
      <email>ShulamithG@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Marius Braun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center - The Center for Liver Diseases</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Silverberg</last_name>
      <email>Dana.Silverberg@sheba.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ziv Ben-Ari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shani Eldar</last_name>
      <email>shaniel@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Helena Katchman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consultorio Medico</name>
      <address>
        <city>Ciudad De Mexico</city>
        <state>MEX</state>
        <zip>6700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Castillo Medina</last_name>
      <phone>+52 553977-7505</phone>
      <email>castillomdn@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Laura Ladron de Guevara Cetina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Lodz</name>
      <address>
        <city>Łódź</city>
        <state>LD</state>
        <zip>91-347</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Osadowska</last_name>
      <email>oska80@o2.pl</email>
    </contact>
    <investigator>
      <last_name>Maciej Jablkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SP CSK im Prof. Kornela Gibińskiego Śląskiego Uniwersytetu Medycznego w Katowicach</name>
      <address>
        <city>Katowice</city>
        <state>SL</state>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izabela Krepska-Rzepa</last_name>
      <email>ikrepska@csk.katowice.pl</email>
    </contact>
    <investigator>
      <last_name>Marek Hartleb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ID Clinic</name>
      <address>
        <city>Mysłowice</city>
        <state>SL</state>
        <zip>41-400</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paulina Michnicka</last_name>
      <email>paulina245@gazeta.pl</email>
    </contact>
    <investigator>
      <last_name>Ewa Janczewska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medyczny Katedra i Klinika Chorób Zakaźnych, Chorób Wątroby i Nabytych Niedoborów Odpornościowych</name>
      <address>
        <city>Wrocław</city>
        <zip>50-220</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Orawczak</last_name>
      <email>adam.orawczak@emc-sa.pl</email>
    </contact>
    <investigator>
      <last_name>Malgorzata Inglot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigacion de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Torres</last_name>
      <phone>787-722-1248</phone>
      <email>rtorres@fdipr.com</email>
    </contact>
    <investigator>
      <last_name>Grisell Ortiz-Lasanta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar Research Institute</name>
      <address>
        <city>Barcelona</city>
        <zip>8003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Viu</last_name>
      <email>aviu@imim.es</email>
    </contact>
    <investigator>
      <last_name>Montserrat Garcia Retortillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Garcia</last_name>
      <email>carogarcia.irycis@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Agustin Albillos Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Olveira Martin</last_name>
      <phone>+3491 207 18 76</phone>
      <email>laura.ucicec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Olveira Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro - Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Luis Calleja Panero</last_name>
      <phone>+34 91 1916025</phone>
      <email>rociomacias@idiphim.org</email>
    </contact>
    <investigator>
      <last_name>José Luis Calleja Panero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario Universitario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Daponte</last_name>
      <phone>+34 986800907</phone>
      <email>sandra.daponte.angueira@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Juan Turnes Vazquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Arias</last_name>
      <email>sarias@idival.org</email>
    </contact>
    <investigator>
      <last_name>Javier Crespo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Romero Gomez</last_name>
      <phone>34955012065</phone>
      <email>mcricoguti@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Manuel Romero Gomez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <state>GBR</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Ayers</last_name>
      <email>andrew.ayers@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Kosh Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Nottingham - Nottingham Digestive Diseases Centre Biomedical Research Unit</name>
      <address>
        <city>Nottingham</city>
        <state>NGM</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Torr</last_name>
      <phone>+44 (0) 115 924 9924</phone>
      <email>bethany.torr@nuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Guruprasad Aithal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal varices</keyword>
  <keyword>belapectin</keyword>
  <keyword>GR-MD-02</keyword>
  <keyword>portal hypertension</keyword>
  <keyword>nonalcoholic steatohepatitis (NASH) cirrhosis</keyword>
  <keyword>NASH</keyword>
  <keyword>cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

